{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-022400","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.262988+00:00","generated_at":"2026-05-22T12:34:42.435183+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed","bullets":["Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.","Non-GAAP EPS $0.08, up 33% YoY; Adjusted EBITDA $19.2M vs $22.6M prior due to divestiture.","Pain Treatments +3.9%, Surgical Solutions +7.0%, Restorative Therapies -35.3% (reflecting rehab divestiture).","FY2025 guidance reaffirmed: revenue $560-570M, Adj. EBITDA $112-116M, Non-GAAP EPS $0.64-0.68.","Entered distribution agreement for XCELL PRP system; added new senior leaders."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-022400","json":"https://secwatch.observer/filing/0001628280-25-022400.json","markdown":"https://secwatch.observer/filing/0001628280-25-022400.md","text":"https://secwatch.observer/filing/0001628280-25-022400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828025022400/0001628280-25-022400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828025022400/bvs-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:34:42.435183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}